Achillion shares spike on promising hep C data

Shares of Achillion Pharmaceuticals jumped 22 percent after the developer announced that preliminary data from an early-stage trial demonstrated that its hepatitis C drug was effective on a once-daily dose using a lower dosage. ACH-1625 spurred meaningful drops in virus levels after five days of treatment. "We remain very encouraged by these compelling results and look forward to advancing the drug into Phase 2 studies in the coming months," Chief Executive Michael Kishbauch said in a statement. Achillion release | Report

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.